Insider Selling: Sana Biotechnology, Inc. (NASDAQ:SANA) Major Shareholder Sells 347,870 Shares of Stock

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) major shareholder Ventures Fund V. Gener Flagship sold 347,870 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $6.57, for a total transaction of $2,285,505.90. Following the completion of the sale, the insider now owns 1,447,791 shares of the company’s stock, valued at $9,511,986.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Sana Biotechnology Stock Performance

NASDAQ:SANA traded up $0.04 during midday trading on Friday, reaching $6.28. 1,094,503 shares of the stock traded hands, compared to its average volume of 1,201,326. Sana Biotechnology, Inc. has a 12 month low of $2.99 and a 12 month high of $9.55. The stock has a market capitalization of $1.20 billion, a P/E ratio of -3.64 and a beta of 0.71. The company has a fifty day moving average of $4.98 and a 200 day moving average of $4.51.

Sana Biotechnology (NASDAQ:SANA – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. On average, analysts predict that Sana Biotechnology, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SANA shares. HC Wainwright started coverage on shares of Sana Biotechnology in a report on Tuesday, May 2nd. They issued a “neutral” rating for the company. Bank of America lowered their price target on shares of Sana Biotechnology from $13.00 to $11.00 in a report on Friday, March 17th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP bought a new position in Sana Biotechnology in the 3rd quarter worth $652,000. Point72 Hong Kong Ltd bought a new position in Sana Biotechnology in the 3rd quarter worth $58,000. Barclays PLC grew its position in shares of Sana Biotechnology by 904.3% in the 3rd quarter. Barclays PLC now owns 293,227 shares of the company’s stock worth $1,759,000 after buying an additional 264,030 shares during the period. Clarius Group LLC grew its position in shares of Sana Biotechnology by 274.6% in the 4th quarter. Clarius Group LLC now owns 46,825 shares of the company’s stock worth $185,000 after buying an additional 34,325 shares during the period. Finally, Bridgefront Capital LLC purchased a new stake in shares of Sana Biotechnology in the 3rd quarter worth about $63,000. 67.12% of the stock is currently owned by institutional investors.

About Sana Biotechnology

(Get Rating)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.